Answers are grounded in this paper and cite their sources.
Objective Preoperative weight loss for bariatric surgery may optimize postoperative outcomes. Antiobesity medications (AOMs) may impact postoperative weight loss. This study evaluated preoperative GLP‐1 receptor agonist use on total weight loss (%TWL) after sleeve gastrectomy. Methods This was a retrospective cohort study of sleeve gastrectomy patients at an academic institution, 2020–2024. Patients were categorized by preoperative weight change: preoperative weight gain (PWG), 0%–5% preoperative weight loss (PWL), 5%–10% PWL, and > 10% PWL. Demographics, comorbidities, AOM use, and %TWL at 2 months, 6 months, and 1 year post surgery were analyzed. Logistic regression identified predictors of achieving > 10% PWL. Results A total of 436 patients were included: PWG ( n = 75), 0%–5% PWL ( n = 173), 5%–10% PWL ( n = 126), and > 10% PWL ( n = 62). %TWL differed significantly between groups at all time points, including 1 year post surgery (PWG: 22.3% ± 9.9%, 0%–5% PWL: 25.9% ± 8.8%, 5%–10% PWL: 27.1% ± 8.8%, > 10% PWL: 31.7% ± 9.9%; p < 0.0001). Overall, 41.5% of patients used AOMs preoperatively, from 22.7% in the PWG group to 64.5% in the > 10% PWL group ( p < 0.001). AOM use was significantly associated with > 10% PWL (OR 3.3, 95% CI 1.8–6.1). Conclusions AOM use was associated with > 10% preoperative weight loss, and greater preoperative weight loss was also coupled with higher cumulative postoperative %TWL.
No takes yet. Share an insight, caveat, or question.
Ying et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: